Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652595 | 0.81 | GPR119 (0.71) | GPR119CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL21847896 | 0.81 | GPR119 (0.55) | GPR119CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL652594 | 0.81 | GPR119 (0.71) | GPR119CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL30456375 | 0.80 | CHRNB2 (0.54) | GPR119CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL15379126 | 0.78 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL652041 | 0.78 | GPR119 (0.60) | GPR119CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL30282995 | 0.77 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL15530708 | 0.77 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL30599872 | 0.76 | GPR119 (0.50) | GPR119CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL30599886 | 0.76 | GPR119 (0.50) | GPR119CHRNB2CHRNA4CHRNA7CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170065575-A1 | NAMPT INHIBITORS | ABBVIE INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20150141398-A1 | NAMPT INHIBITORS | ABBVIE INC. | 2015-05-21 | — | — | US | disclosed |
| EP-2847181-A1 | PYRIDAZINE AND PYRIDINE DERIVATIVES AS NAMPT INHIBITORS | AbbVie Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| US-8975398-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-03-10 | — | — | US | disclosed |
| WO-2013170115-A1 | PYRIDAZINE AND PYRIDINE DERIVATIVES AS NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130303510-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141398-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | GPR119 662/4885CHRNB2 1991/4885CHRNA4 2792/4885 |
| US-20170065575-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | GPR119 662/4885CHRNB2 1991/4885CHRNA4 2792/4885 |
| US-20130303510-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | GPR119 662/4885CHRNB2 1991/4885CHRNA4 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.